O
Ochre Bio
Develops RNA therapies for chronic liver diseases, a leading cause of death globally
About Ochre Bio
Ochre Bio is a biotechnology startup that operates in the healthcare sector, specifically focusing on liver disease treatment. The company's primary mission is to improve outcomes for liver transplant patients, addressing the significant gap in the supply of healthy donor organs. This issue is particularly acute among minority communities, who are disproportionately disadvantaged.
Read full description
Ochre Bio's business model is centered around the development of effective therapies for chronic liver disease, thereby reducing the reliance on liver transplants. The company's scientific teams, with their extensive experience in genomics and drug development, are committed to making healthy livers available for patients everywhere.
The company was founded in 2019 and named in honor of Nobel laureate, Sydney Brenner, known for his remarkable scientific creativity. The team at Ochre Bio is guided by the principles of Clarke’s, Murphy’s, and Wheaton’s laws, which emphasize the importance of scientific rigor, preparedness for unexpected outcomes, and the ethical use of technology.
Ochre Bio's clients are primarily patients suffering from chronic liver disease who are in need of liver transplants. The company operates in the biotechnology market, specifically within the sub-sector of genomics and drug development.
The company generates revenue through the development and sale of its therapeutic solutions. As a biotech firm, it may also earn income through partnerships with larger pharmaceutical companies, licensing agreements, and potentially, government grants for research and development.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Oxford, United Kingdom
- Employees
- 60
- Open positions
- None listed
- Dealroom signal
- 67.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Genetics and genomics, Core AI
- Technology
- Artificial Intelligence, Hardware, Big Data, Deep Tech, Machine Learning
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2023 | — | — | CoastCap · Gaingels | — |
| SERIES A✓Equity / VC | Oct 2022 | $30M | $120M | EIT Health · Selvedge Venture · Kristen Fortney · Hermes Epitek | ↗ |
Growth signals
Latest recorded traffic for Ochre Bio is 5.1K monthly website visits, up 34.2% over the last three months. Ochre Bio's team declined 9.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Y Combinator
Khosla Ventures
BACKED VC
Apollo Health Ventures
Hoxton Ventures
Hermes Epitek
Selvedge Venture
Series A11 investors entered at this stage
Acequia Capital
FAST — by GETTYLAB
EIT Health
Kristen Fortney
AixThera- MCMarty Chavez
Alice Zhang
Lifeforce Capital
LifeLink Ventures
CoastCap
Gaingels
Other known investors7 additional known investors
- ATAlasdair Thong
Calm Ventures
Expa
Norrsken VC
Pathway Bioventures
Patrick Schneider-Sikorsky
TGM
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ochre Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ochre Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.